AstraZeneca
NEWS
The triple combination therapy does not use a chemotherapy agent in its experimental treatment for an aggressive blood cancer.
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
Boston and its surrounding communities, particularly the community of Cambridge, have become the hottest biotech hotspot on the East Coast of the United States.
Full data will be shared at a later conference, but the study marked the first time a BTK inhibitor showed benefit as a monotherapy in CLL.
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
AstraZeneca reported first-quarter financials, with Product Sales growing 10% (14% at CER) to $5.465 billion. What is more startling, and completely in accordance with the company’s stated goals, Global Oncology sales increased by 54%.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo Company for trastuzumab deruxtecan (DS-8201).
The rumors speculated that AstraZeneca planned to acquire Aveo in the second quarter of this year in order to gain the company’s kidney cancer drug, Tivozanib.
JOBS
IN THE PRESS